Paxlovid (nirmatrelvir-ritonavir) is effective at preventing hospitalization and death from COVID-19, but few people use it. A paper by SteelFisher et al. (2024) surveyed 1,430 American adults to find out why. Their survey revealed patients had a lack of awareness of the treatment as well as misinformation about the treatment (among those who were aware of it). Specifically:
A majority of respondents (85 percent) had no or low awareness of Paxlovid, including 31 percent who had never heard of it. Even among those who were aware of the drug, many held misperceptions about its effectiveness (39 percent), adverse effects (86 percent), and requisite timing (61 percent) that could lead to underuse. Lower awareness and misperceptions were more common among medically vulnerable and disadvantaged populations who might benefit most from Paxlovid access, including adults unvaccinated against COVID-19, those with lower levels of education, and Black and Hispanic or Latino adults.
You can read the full paper here.
Disclaimer :
This article is solely for informational purposes, any medical information contained is not a substitute for professional medical advice and readers should not rely on it as such.
If you believe there may be errors or misinformation in this article, we encourage you to contact the webmasters by messaging the provided contact information.
Your feedback is valuable, and we are committed to rectifying any inaccuracies. Please note that the content will be re-evaluated, and corrections will be made as necessary following your submission.